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Introduction
The risk of colorectal cancer (CRC) is linked to lifestyle, dietrelated factors, chronic inflammatory states, increasing age and hereditary disorder (1) . CRC remains the third most common cancer, causing significant morbidity and mortality (2) . Approximately 135 430 patients have been diagnosed with CRC and approximately 37% of CRC patients died in the United States in 2017 (3) . Despite advances in surgery and chemotherapy to treat CRC, preventive measures are still required.
Spontaneous and chemical-induced mouse models are mostly used to study experimental CRC, because, these models exhibit a similar pathology, which correlates with the progression of human CRC (4) . The genetic mouse model for CRC includes gastrointestinal tract studies using adenomatous polyposis coli (APC Min/+ ) mice in which CRC results from the mutation at codon 850 of the APC gene (5) , which causes familial adenomatous polyposis, an autosomal dominantly inherited disease that eventually leads to colorectal malignancy (6) . Similarly, the azoxymethane/dextran sodium sulfate (AOM/DSS) model is an excellent experimental model for studying CRC inflammation and pathogenesis (7) . This model is strongly linked to chronic colitis-associated colon cancer (CAC) in humans (8) . Moreover, the multistep process of carcinogenesis characterized by the canonical phases of initiation, promotion and progression has been entirely reproduced in this model (7) .
Multiple signaling pathways are involved in CRC pathogenesis and more specifically, inflammatory activity is a significant contributing factor (9) . Studies have shown that PI3K/AKT activates NF-κB signaling in the presence of tumor necrosis factoralpha (TNF-α) and interleukin-1 (IL-1) by phosphorylating the p65 subunit (10) . On the other hand, blocking TNF-α activation reduced the number and size of the tumors in the AOM/DSS model (11) . Both, IL-6 and TNF-α are well-established tumor-promoting cytokines, and their upregulation has been frequently associated with sporadic and colitis-associated CRC (12) . Among the different mediators of inflammation, the cyclooxygenases (COXs) are also linked as a causative factor for CRC (13) . COX-2 is the inducible isoform, and it is controlled by growth factors and different cytokines such as IL-1β, IL-6, and TNF-α (14) .
AKT, a serine/threonine-specific protein kinase is one of the most frequently deregulated signaling pathways in human cancers, including CRC (15) . Activation of the AKT pathway plays a crucial role in cell survival, proliferation, migration and differentiation, contributing to tumorigenesis and tumor metastasis. CRC resistant to chemotherapy or radiotherapy is often associated with AKT overexpression and activation. Recent studies have demonstrated that AKT is an attractive target to recognize specific inhibitors with suitable pharmaceutical properties (16) . Clinical studies have shown that AKT activation is increased in 46% of CRC, and it is associated with the Ki-67 proliferation index (17) . Furthermore, the important function of AKT is to induce the pro-survival signaling by increasing the GSK-3β/mTOR/NF-κB expression in inflammation conditions, which ultimately leads to resistance to apoptosis in colon cancer (18) . Notch signaling, which is constitutively activated in CRC, also cross talks with the p65 subunit of NF-κB; and inhibition of this signaling axis suppresses the cell growth and induced apoptosis (19) . Notch signaling has been shown to regulate the colonic goblet cells and stem cells/progenitor cells (20) . Thus, Notch signaling is critical for maintaining intestinal development and homeostasis.
The role of diet in modulating CRC risk is well-accepted, and natural compounds have been shown to be safe over time. Previous studies on nutraceutical foods have validated the significance of natural compounds which reduce the incidence of cancer including CRC (21) . Withaferin A (WA) is a small natural molecule, an herbal dietary agent derived from the plant Withania somnifera that is used extensively in Asian and African traditional medicine to treat various ailments (22) . Our earlier in vitro and in vivo studies demonstrated the therapeutic and preventive effect of WA against colon cancer (23, 24) . In this study, we demonstrate the chemoprevention efficacy of WA in the APC Min/+ and AOM/DSS mouse models by inhibiting cell proliferation (Ki67), survival (pAKT, Notch1 and NF-κB) and inflammation (IL-6, TNF-α and COX2) markers.
Materials and methods
WA was purchased from Nucleus Biopharma (King of Prussia, PA) for the in vivo mouse studies. Primary monoclonal antibodies specific for phospho-AKT (ser473), p65, Notch1 and Ki67 were purchased from Cell Signaling (Danvers, MA). All animals were housed and experiments were performed in accordance with Institutional Animal Care and Use Committee and approved by University of Louisville.
APC
Min/+ model C57BL/6 -APC Min/+ mice of both sexes with a starting age of 5-6 weeks were purchased from Jackson Laboratory (Bar Harbor, ME) and divided into two groups of 18 animals (9 males and 9 females) each. Control group received sesame oil as a vehicle and treatment groups received WA (4 mg/kg) by oral gavage for 5 days/week for 12 weeks. Mice were monitored every day for clinical signs of illness such as rectal bleeding, rectal prolapse and body weight loss. At the end of 12th week treatment, mice were sacrificed and the duodenum, jejunum, ileum and colon were removed. The organs were then flattened on filter paper and fixed overnight in 10% buffered formalin. The following day, segments were washed with phosphate-buffered saline and stained with 0.2% methylene blue in phosphate-buffered saline. The number, location and size of visible polyps were determined at ×10 magnification using a Nikon Smz800 microscope (Westmont, IL) (by two independent and blinded investigators). Based on polyps size, the intestinal tract was classified into four categories (0-1, 1-2, 2-3, >3 mm).
After the count and size measurements of polyps, the segments were Swiss-rolled and then embedded in paraffin for histological analysis.
AOM/DSS model
For the AOM/DSS model, FVB/NJ mice of both sexes were purchased from Jackson Laboratory. Ten mice were assigned per group (control and treatment) AOM (10 mg/kg) was injected intraperitoneally. After 1 week, 2% DSS was administered in the drinking water for 7 days, followed by 2 weeks of regular water. This cycle was repeated three times. In the treatment group, mice received oral WA (3 mg/kg) for 5 days/week for 10 weeks. At the end of the experimental period, mice were euthanized using CO 2 and the entire colon was removed. The number of macroscopic tumors was counted and the tumor volume was measured. Subsequently, the colons were fixed in 10% neutral-buffered formalin for 24 h, and transferred to 70% ethanol and Swiss-rolled for paraffin embedding and histological analysis.
RNA extraction and RT-PCR
Total RNA was extracted from polyps from the duodenum, jejunum, ileum and colonic segments of the APC Min/+ mice and colonic tumors from the AOM/DSS mice using the TRIzol reagent and dissolved in diethyl pyrocarbonate water. Complementary DNA was then synthesized from total RNA with an Applied Biosystems complementary DNA synthesis kit using SYBR Green supermix (Qiagen, Valencia, CA). Quantitative RT-PCR was performed as described previously (25) .
Histology and immunohistochemistry
For histopathological examination, the complete gastrointestinal tract (paraffin blocks) were sectioned into 4 μm lengths and processed for hematoxylin and eosin staining, as described previously (26) . A boardcertified pathologist examined the all stained slides. For immunohistochemical analysis, the complete gastrointestinal tract tissue was fixed in 10% buffered formalin and processed as described previously (26) . The specific antibodies were obtained for pAKT (ser473), p65, Notch1 and Ki67 were obtained from Cell Signaling (Danvers, MA) and used to visualize the expression of specific proteins in tissue samples.
Statistical analysis
Multiplicity of the tumors (AOM/DSS mice), defined as mean number of tumors/mice, was analyzed by unpaired Student's t-test with Welch's Correction. The tumor incidence (AOM/DSS mice) (percentage of mice with colon tumors) was analyzed by Fisher's exact two-tailed test. All the other data were expressed as the mean ± standard deviation or standard error of mean (SD or SEM). Significant differences between the groups were determined using the unpaired Student's t-test or one-way analysis of variance. Significant differences were established at P < 0.05. All statistical calculations were performed using GraphPad Prism 7.03 software (La Jolla, CA). ***P < 0.001, **P < 0.01, *P < 0.05 versus vehicle control of APC Min/+ and AOM/DSS mice. Not significant (n.s).
Results
Oral administration of WA prevents the sporadic intestinal tumor in APC Min/+ mice Control mice developed approximately 42 polyps in the ileum, 30 polyps in the jejunum, 10 polyps in the duodenum and 8 polyps in the colon after 12 weeks. However, WA-fed (4 mg/ kg) mice showed a significant reduction in polyps in the ileum 43% (P < 0.001), jejunum 32% (P < 0.025), duodenum 33% (P > 0.05) and colon 59% (P < 0.01; Figure 1A ). Size distribution analysis of adenomatous polyps in WA-treated mice showed a reduced number of <1-mm size polyps by 36% (P < 0.05) in the ileum, 35% (P < 0.01) in the jejunum and 28% in the duodenum (P > 0.05) compared with vehicle-treated groups. Polyps of 1-2 mm in size were reduced by 28% (P > 0.05) in the ileum, 16% (P > 0.05) in the jejunum and 15% (P > 0.05) in the duodenum. Polyps of 2-3 mm in size were reduced by 70% (P < 0.05) in the ileum, 60% (P > 0.05) in the jejunum and 80% (P < 0.05) in the duodenum ( Figure 1C , D and E) compared with vehicle-treated mice, indicating differential effects of WA depending upon polyp size and the intestinal segment. The most prominent WA effect was observed on larger-sized polyps (>3 mm), which were undetectable in the jejunum and ileum and colon ( Figure 1C , D and E). WA reduced the total number and size of colonic polyps <1 mm and 1-2 mm in size by 60% (P < 0.01) and 18% (P > 0.05), respectively ( Figure 1F ). None of the WA-treated mice showed 2-3 mm and >3 mm size polyps, showing a complete suppression, which suggests that WA effectively inhibits progression of colonic polyps. During the experimental period, WA-treated mice did not show any significant differences from vehicle-treated mice in body weight ( Figure 1B) . In APC Min/+ mice, all polyps were histologically identified as adenomas. However, the mice administrated WA showed less adenoma in both the duodenum and ileum, and there was no carcinogenesis or adenoma in the jejunum and colon ( Figure 1G ).
WA administration prevents chemically induced intestinal tumor in AOM/DSS mice
The antitumor effect of WA (3 mg/kg/body wt) was evaluated in AOM/DSS-induced tumorigenesis. Oral WA did not cause any apparent clinical toxicity or significant changes in body weight compared with AOM/DSS control ( Figure 2A ). AOM/DSS treatment shortened the colon length ( Figure 2B ) and increased the 300 µm (G). ***P < 0.001, **P < 0.01, *P < 0.05 versus vehicle control of APC Min/+ . n.s, not significant. The bars represent mean ± SD or SEM of 18 mice/group colon weight because of the tumor burden compared with the WA-treated group. Multiple colonic tumors were either flat or polypoid in control mice and the tumors were confined to the middle and distal colon ( Figure 2C ). No significant difference in the incidence of colon tumors were seen in WA-treated versus vehicle-treated AOM/DSS mice ( Figure 2D ). Further, WA treatment significantly reduced tumor multiplicity (50%, P < 0.05; Figure 2E ) in AOM/DSS mice. Notably, WA-treated mice reduced the lesion frequency and size. A significant reduction (P < 0.05) was observed in tumor of size 2-3 mm in WA-treated group ( Figure 2F) . Correspondingly, the average tumor load was lower in WA-treated mice. In hematoxylin and eosin staining, AOM/ DSS animals showed high-grade dysplasia, colonic adenoma and tissue inflammation. Administration of WA reduced all pathological abnormalities in the mice ( Figure 2G ).
The expression profile of colonic inflammatory mediators was regulated by WA
Chronic inflammation stimulates intestinal tumorigenesis by a variety of pro-inflammatory molecules and growth factors. In this experiment, we analyzed the cytokine and inflammatory profiles in the adenomatous polyps from the duodenum, jejunum, ileum and colon of APC Min/+ mice and colonic tumors from AOM/DSS mice. We observed that IL-6, TNF-α and COX-2 mRNA expression levels were significantly downregulated in adenomatous polyps or tumor from the duodenum, jejunum, ileum or colon of WA-fed APC Min/+ and AOM/DSS mice compared with controls ( Figure 3A , B, C and E). A significant upregulation of TNF-α expression was seen in WA-treated colonic adenomatous polyps as compared with controls of APC Min/+ mice polyps ( Figure 3D ). These data suggested that the inhibition of 
WA treatment inhibits AKT activation in small and large intestinal polyps in APC Min/+ and AOM/DSS mice
Tumor growth in CRC is often attributed to constitutive activation of AKT. Antiproliferative effects of WA on spontaneous and chemically induced intestinal tumorigenesis were evident. To dissect the underlying mechanism, we examined the effect of WA administration on AKT activation by immunohistochemistry. Microscopic quantification of all three small intestinal segments and colon indicated strong pAKT (ser473) expression in the nucleus and cytosol of adenomas polyps in the APC Min/+ and tumors in AOM/DSS controls, whereas significantly decreased pAKT expression was seen in the polyps or tumors of WA-administered group. The quantification of phospho-AKT expression showed a significant reduction by 39% in the polyps of ileum (P < 0.02), 45% (P < 0.01) in the polyps of jejunum, 45% (P < 0.05) in the polyps of duodenum and 53% (P < 0.05) in the polyps of colon in WA-treated mice compared with APC Min/+ control mice ( Figure 4A ). In AOM/DSS mice, pAKT-positive cells were significantly reduced by WA treatment by 46% (P < 0.01) in the tumors of colon compared with control tumors ( Figure 4B ).
Inhibitory effects of WA on p65 expression in

APC Min/+ and AOM/DSS models
We also used immunostaining to examine p65 expression in different portions of the small intestine and colon in the control and WA groups. Higher p65 expression is considered to be the most valuable malignant marker of adenomatous polyps in APC Min/+ and tumors of the AOM/DSS mice. Quantification of immunostaining showed that WA significantly decreased p65 expression by 50% (P < 0.002) in the polyps of ileum, 46% (P < 0.02) in the polyps of jejunum, 42% (P < 0.05) in the polyps of duodenum and 45% (P < 0.05) in the polyps of colon compared with the polyps of APC Min/+ control group ( Figure 5A ). WA administration in AOM/DSS mice significantly suppressed p65 
WA downregulates Notch1 expression in AOM/DSS and APC Min/+ mice
The cross talk between p65 and Notch1 is the mainstay of epithelial-mesenchymal transition (EMT) and thus tumorigenesis in CRC (27) . Thus, it is important to examine the effect of any treatment on correlated signaling pathways such as p65 and Notch1. In APC Min/+ mice, Notch1 immunoreactivity was reduced by 45% (P < 0.002) in the polyps of duodenum, 62% (P < 0.05) in the polyps of jejunum, 32% (P < 0.05) in the polyps of ileum and 49% in the polyps of colon (P < 0.002) in WA-treated mice when compared with controls ( Figure 6A) . Notably, immunohistochemistry analysis suggested that WA significantly decreased Notch1 expression by 30% (P < 0.05) in the tumor of colon compared with the AOM/DSS control group ( Figure 6B) . Collectively, these results demonstrate the antiproliferative and antitumorigenic effect of WA.
WA reduces proliferation in APC Min/+ and AOM/ DSS mice
Excessive proliferation may be responsible for the progression of adenocarcinoma polyps. The reduction in size and frequency of polyps in WA-treated mice suggests the downregulation of and AOM/DSS controls. Quantification of Ki67 staining showed that WA treatment decreases Ki67-positive cells by 42% (P < 0.05) in the polyps of duodenum, 55% (P < 0.01) in the polyps of jejunum, 30% (P < 0.05) in the polyps of ileum and 50% (P < 0.05) in the polyps of colon in WA-treated mice compared with vehicletreated APC Min/+ mice (Supplementary Figure 1A) . Additionally, 3 mg/kg WA-treated AOM/DSS mice tumors showed a reduction 
Discussion
Recently, cancer prevention involving dietary compounds has been shown to be a promising and cost-effective approach to reduce CRC incidence and morbidity by suppressing precancerous events before clinical disease is present. In this study, we demonstrated the chemopreventive effect of WA on spontaneous intestinal and chemically induced colon carcinogenesis in APC Min/+ and AOM/DSS mice. Excessive growth and inadequate apoptosis are often associated with the development of intestinal tumorigenesis (28) . The early stage of colon cancer is characterized by a benign adenoma that could progress to adenocarcinoma with high-grade dysplasia (29) . The APC Min/+ mouse model is unique because tumors appear spontaneously in the gastrointestinal tract, rather than through induction using a carcinogen. APC Min/+ mice develop adenomas as the outcome of inactivation of the APC tumor suppressor gene, which is known to be associated with pathogenesis in most colon cancers in humans (30) . In this study, we showed, for the first time, that WA significantly inhibits the formation of adenomatous polyps in APC Min/+ mice, which was demonstrated by WA administration that completely suppressed >3-mm polyps in the small intestine (jejunum and ileum) and colon.
The AOM/DSS-induced neoplasm mimics human CAC (31). Thus, experiments using these models are probably to be appropriate to use in the design of human chemoprevention clinical trials. AOM causes colonic carcinogenicity resulting in the formation of O 6 -methylguanine adducts upon metallic activation, whereas cycles of DSS treatment induce chronic inflammation in colons, which resembles inflammatory bowel disease (32) . WA administration effectively reduced the inflammation associated with colitis in this study and decreased the multiplicity of colonic tumors in mice, as reflected by marked amelioration of clinical symptoms and a reduction in the incidence of colonic dysplasia. This protective effect was further confirmed in a decrease in the intensity of colonic damage and nuclear cell alterations, as evidenced by histological findings. However, no significant difference in tumor incidence between WA-treated and vehicletreated mice was seen, which suggests that a higher concentration of WA may require to prevent the tumor incidence in AOM/ DSS models. Similar results were shown in 7,12-dimethylbenz[a] anthracene (DMBA) and 12-O-tetradecanoylphorbol 13-acetate-induced skin tumor models and mammary tumor virus (MMTV)-neu mice that WA significantly inhibited the tumor multiplicity, but not the tumor incidence (33, 34) . Several naturally occurring dietary phytochemicals were shown to inhibit formation of adenomatous polyps and tumor multiplicity in APC Min/+ and AOM/DSS mice, which is consistent with our results (35, 36) .
Elevated AKT levels are present at the early stages of intestinal carcinogenesis (37) . AKT is shown to be overexpressed in rat premalignant colonocytes and in 42% of the tumors that developed (38) . We found that WA administration to APC Min/+ and AOM/DSS mice dramatically decreased AKT activation. These results are in agreement with our earlier findings, wherein WA administration downregulated pAKT expression in AKT overexpressing xenograft tumors and transgenic mice (TRAMP and PTEN) in prostate cancer mouse models (24, 39, 40) . We previously reported that WA inhibited AKT-induced CRC cell growth in preclinical CRC models (24) , which was further confirmed by another group in MMTV-neu mouse model (41) . We and others have shown that WA appears to target only cancer cells and cause a minimal toxic effect on normal human gingival fibroblast (26) , endothelial (42) and mammary epithelial cells (43) . WA specifically targets cancer cells by inducing reactive oxygen species-mediated cell death without affecting normal mammary epithelial cells (44) .
Many in vivo studies have further confirmed that WA exhibits selective cytotoxicity against tumor cells (24, 39, 45) . A randomized, double-blind, clinical study suggested that three doses of W. somnifera extract (400 mg) for a month appears to be a welltolerated dose, and also significantly reduced serum triglycerides in patients (46) and a similar study was reported earlier on the no adverse effect on human (47) .
Another key player in inflammation and carcinogenesis is the NF-κB-COX-2 signaling pathway, which has also been shown to affect APC gene mutation in human intestine and colon cells. Thus, it is an important treatment target for CRC (48) . An increase in inflammatory stress is reported to be correlated with the development of intestinal polyps in APC Min/+ mice. Notably, NF-κB is abnormally activated in 50% of CRC patients and those with colitis-associated tumors. Additionally, proinflammatory cytokines, such as TNF-α, IL-6 and IL-1β, or transcription factors such as NF-κB, which are induced by these cytokines, have been identified as potential targets for anticancer therapy (49) . COX-2 is an immediate-early growth response gene product. NF-κB and Wnt signaling have both been shown to regulate COX-2 expression. COX-2 overexpression has been shown to increase AOM-induced tumor formation (50) . COX-2 and cyclin D1 are induced by TNF-α in colonic cells that have the NF-κB binding site in their promoters (51) . In this study, expression of the pro-inflammatory mediators, COX2 and NF-κB significantly suppressed by WA administration in both the mouse models. This decrease in NF-κB expression coupled with a dramatic downregulation of COX-2 and Notch1 expression could be the underlying mechanisms responsible for the anti-inflammatory and antitumorigenic effects of WA administration, ultimately leading to the suppression of polyps or tumors in the intestines and colon in APC Min/+ and AOM/ DSS mice. Although the increased mRNA expression of TNF-α was seen in the colonic polyps of WA-treated mice, the number of polyps is significantly lesser than the controls that suggest TNF-α would not have played any significant role in tumor inhibition or WA could overcome TNF-α mediated carcinogenic effect.
This study demonstrates an in vivo antiproliferative efficacy of WA in intestinal and colonic polyps of APC Min/+ and tumors of AOM/DSS mice that is evidenced by Ki67 immunostaining. Proliferation is an integral part of cancer development and progression in the early stage of intestinal colon carcinogenesis. Thus, identification of chemopreventive agents that downregulate cell proliferation is recognized as a useful strategy to control colon tumor growth. The expression of Ki67 is widely used to study cell proliferative activity, that correlates with metastasis and clinical tumor stage. Additionally, Ki67 expression is significantly higher in malignant tissues with poorly differentiated tumor cells compared with normal tissue. The effect of WA observed in this study is supported by the reduction of cell proliferation in its suppression of early stage carcinogenesis, antiproliferative and anti-inflammatory mechanisms. Previous studies demonstrated that WA inhibits early event of colon carcinogenesis by inhibiting tumor promoter IDH1 gene activity and altering mitochondrial function (52) . Interestingly, the half-life (t1/2) of WA (45 min) was higher than withanolide A, a group of secondary metabolites obtained from W. somnifera (the plant source of WA) in orally administered Swiss Albino female mice. Pharmacokinetics studies using high-performance liquid chromatography-mass spectrometry/mass spectrometry determined that WA has one and a half times more relative bioavailability as compared with withanolide A (53) . Another study has shown that WA attains peak plasma concentration of up to 2 µm with a half-life of 1.36 h in 7-to 8-week-old BALB/c mice at a single dose of 4 mg/kg (54) . These studies suggest that higher bioavailability of WA and thus impart better efficacy in diseased condition.
Overall, these results provide compelling evidence that WA prevents the development of intestinal and colonic neoplasia in APC Min/+ and AOM/DSS-induced CRC in mice by inhibiting cancer cell proliferation (Ki67), ameliorating colon inflammatory processes and limiting the activation of a transcription factor (NF-κB) that modulates the expression of Notch1 signaling. WA is thus a promising natural protective/preventive agent against sporadic and colitis-associated CRC with the potential to help maintain tissue homeostasis in the human colon.
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